Akari Therapeutics, Plc
NASDAQ Capital MarketTotal Valuation
Akari Therapeutics, Plc carries a market capitalization of 21.42M, placing it among publicly traded companies globally.
| Market Cap | 21.42M |
| Enterprise Value | N/A |
Share Statistics
Akari Therapeutics, Plc currently has 140.03B shares outstanding.
| Shares Outstanding | 140.03B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 77,189.35 |
| P/TBV Ratio | -122,625.88 |
| P/FCF Ratio | -1.30 |
| P/OCF Ratio | -1.30 |
Financial Position
Akari Therapeutics, Plc maintains a current ratio of 0.60, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.60 |
| Quick Ratio | 0.55 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -13.89 |
Financial Efficiency
| Return on Equity (ROE) | -140.09 |
| Return on Assets (ROA) | -69.16 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -1.86M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Akari Therapeutics, Plc's stock has declined approximately -69.70779% over the past 52 weeks. The 50-day moving average sits at 9.13, while the 200-day moving average is 9.19.
| Beta (5Y) | N/A |
| 52-Week Price Change | -69.70779% |
| 50-Day Moving Average | 9.13 |
| 200-Day Moving Average | 9.19 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -13.68M, while operating income came in at -13.68M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -13.68M |
| Pretax Income | -32.82M |
| Net Income | -30.96M |
| EBITDA | -13.68M |
| EBIT | -13.68M |
| Earnings Per Share (EPS) | -22.70 |
Balance Sheet
Total book value stands at 18.60M, with working capital of -5.61M providing operational flexibility.
| Cash & Cash Equivalents | 7.69M |
| Total Debt | N/A |
| Net Debt | -7.00M |
| Equity (Book Value) | 18.60M |
| Book Value Per Share | 0.00 |
| Working Capital | -5.61M |
Cash Flow
Akari Therapeutics, Plc produced -10.76M in operating cash flow over the past twelve months.
| Operating Cash Flow | -10.76M |
| Capital Expenditures | N/A |
| Free Cash Flow | -10.76M |
| FCF Per Share | -7.89 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.00 |
| FCF Yield | -76.94 |
Stock Splits
Akari Therapeutics, Plc's most recent stock split took place on March 31, 2026 with a 40:1 split ratio.
| Last Split Date | 3/31/2026 |
| Split Ratio | 40:1 |
Scores
Akari Therapeutics, Plc posts an Altman Z-Score of 42,943.76, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 42,943.76 |